Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Gains from Investment Securities (2018 - 2025)

Historic Gains from Investment Securities for Serina Therapeutics (SER) over the last 8 years, with Q3 2025 value amounting to -$1.0 million.

  • Serina Therapeutics' Gains from Investment Securities rose 8441.79% to -$1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.8 million, marking a year-over-year increase of 7719.39%. This contributed to the annual value of -$13.2 million for FY2024, which is 112154.13% down from last year.
  • As of Q3 2025, Serina Therapeutics' Gains from Investment Securities stood at -$1.0 million, which was up 8441.79% from $1.0 million recorded in Q2 2025.
  • In the past 5 years, Serina Therapeutics' Gains from Investment Securities registered a high of $3.4 million during Q2 2021, and its lowest value of -$9.3 million during Q2 2024.
  • Over the past 5 years, Serina Therapeutics' median Gains from Investment Securities value was -$103500.0 (recorded in 2022), while the average stood at -$868375.0.
  • As far as peak fluctuations go, Serina Therapeutics' Gains from Investment Securities tumbled by 1521111.11% in 2024, and later surged by 11075.27% in 2025.
  • Quarter analysis of 5 years shows Serina Therapeutics' Gains from Investment Securities stood at $3.4 million in 2021, then crashed by 99.85% to $5000.0 in 2022, then tumbled by 460.0% to -$18000.0 in 2023, then crashed by 15211.11% to -$2.8 million in 2024, then soared by 62.12% to -$1.0 million in 2025.
  • Its Gains from Investment Securities was -$1.0 million in Q3 2025, compared to $1.0 million in Q2 2025 and -$989000.0 in Q1 2025.